Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Endocrinology

When Thyroid Tests Are Normal: Understanding Euthyroid Graves Orbitopathy

At a Glance

Euthyroid Graves orbitopathy can cause bulging eyes, swelling, or double vision even when thyroid hormone tests are normal. Doctors combine an eye examination with specialized antibody testing and MRI or CT imaging because routine tests can miss it and other orbital diseases can look similar.

It can be deeply confusing to experience bulging eyes, double vision, or eyelid swelling only to be told your thyroid blood tests are perfectly normal. This condition is known as Euthyroid Graves Orbitopathy (EGO). While most people with Thyroid Eye Disease (TED) have an overactive thyroid, about 5% to 8% of patients maintain normal thyroid hormone levels—at least initially [1][2].

EGO is unique because it frequently affects only one eye or is noticeably worse on one side (asymmetric) [3]. Because the standard “thyroid screen” comes back clear, the diagnosis often depends on specialized antibody testing and detailed imaging of the eye sockets.

The Biology of EGO: A Tale of Two Receptors

Even when your thyroid gland is behaving normally, your immune system may be producing antibodies that mistakenly target the tissues behind your eyes. The biology of EGO centers on orbital fibroblasts, specialized cells located in the fat and muscle behind the eye [4].

These cells contain two key receptors that “listen” to signals from the immune system: the TSH receptor (TSHR) and the IGF-1 receptor (IGF-1R). In EGO, these two receptors physically link up and “talk” to each other in a process called crosstalk [4][5].

When stimulating antibodies bind to these receptors, they trigger a chain reaction:

  • Hyaluronan Buildup: The cells produce large amounts of hyaluronan, a sugar molecule that acts like a sponge, soaking up water and causing the tissues to swell [6][7].
  • Fat Expansion: The antibodies signal the fibroblasts to turn into fat cells, increasing the volume of fat behind the eye and pushing the eyeball forward (proptosis) [8].
  • Muscle Swelling: The extraocular muscles—the muscles that move your eyes—become inflamed and enlarged, which can lead to double vision or a “tight” feeling when looking around [2][9].

The Diagnostic Pitfall: Not All Antibody Tests Are Equal

One of the biggest hurdles in diagnosing EGO is that standard blood tests may miss the culprit. Doctors often order a test called TRAb or TBII (Thyroid Binding Inhibitory Immunoglobulin). This test measures the inhibition of antibody binding to the receptors.

However, in EGO, these standard binding assays can be negative even when the disease is active [10]. A more specialized test called a TSI (Thyroid Stimulating Immunoglobulin) or TSAb bioassay is often more helpful because it measures the stimulating activity of the antibodies [11][12].

In specific study populations, functional TSI assays have detected the disease in approximately 86% to 88% of these patients, though assay sensitivity varies [13][14]. If your standard thyroid tests are normal but your eyes are changing, a negative TRAb test requires clinical reassessment rather than automatic exclusion of EGO [10][15].

Confirming the Diagnosis with Imaging

Because EGO can look like other conditions, doctors rely on MRI or CT scans to see exactly what is happening inside the orbital (eye) cavity. Imaging and antibody tests are always interpreted alongside a clinical examination.

Supportive features of EGO on a scan involve:

  • Muscle Enlargement: Specifically, the muscles that move the eye appear swollen.
  • Tendon Sparing: A classic, though not universally required, feature is that the “belly” of the muscle swells, but the tendons (the thin parts that attach the muscle to the eye) remain normal [2].
  • Bilateral Changes: Even if only one eye looks affected to the naked eye, imaging may show some degree of change in both eyes [16]. However, true unilateral disease can also occur.

Ruling Out the “Look-Alikes”

Because EGO often presents asymmetrically, doctors must carefully rule out other conditions that cause orbital swelling:

  • IgG4-Related Orbital Disease: A fibroinflammatory condition that often involves the tear glands (lacrimal glands). A biopsy is considered by an orbital specialist if the clinical and imaging picture is atypical [17].
  • Idiopathic Orbital Inflammation: Previously called “pseudotumor,” this is a rapid, often painful swelling of the eye tissues. Unlike EGO, it often involves the muscle tendons as well as the muscle belly [18].
  • Orbital Tumors: While rare, tumors or the spread of cancer from elsewhere (metastasis) can cause one eye to bulge. If imaging is unclear or the disease does not respond to standard treatments, a biopsy is necessary to rule these out [19][20].
  • Orbital Sarcoidosis: A systemic inflammatory disease that can cause clumps of cells (granulomas) to form in the eye muscles, mimicking EGO [21].

Even if your thyroid function is normal today, clinical studies indicate that some patients (roughly 24% in certain cohorts) may develop an overactive thyroid (hyperthyroidism) later [22]. Regular follow-ups with an endocrinologist are essential to monitor these levels over time [23][24].

Common questions in this guide

Can Graves eye disease happen when my thyroid tests are normal?
Yes. Euthyroid Graves orbitopathy is a form of thyroid eye disease in which immune activity affects the tissues behind the eyes even though thyroid hormone levels are normal. It can cause bulging eyes, eyelid swelling, double vision, or symptoms that are worse on one side.
What does a negative TRAb test mean if I have eye changes?
A negative TRAb or TBII result does not automatically rule out euthyroid Graves orbitopathy because these binding tests can miss active disease. A TSI or TSAb functional assay may be more informative because it measures whether antibodies stimulate the relevant receptors.
What can an MRI or CT scan show in euthyroid Graves orbitopathy?
Scans may show swelling and enlargement of the muscles that move the eyes, often with the muscle tendons left relatively normal. Imaging may show changes in both eye sockets even when one eye looks more affected, but the scan must be interpreted with the examination and antibody results.
Why might one eye look worse than the other?
Euthyroid Graves orbitopathy often causes unequal changes, so one eye may bulge or swell more than the other and, in some cases, only one eye appears affected. Imaging can still reveal milder involvement of the other eye, although true one-sided disease can occur.
How do doctors tell EGO from other causes of a swollen or bulging eye?
Doctors compare the examination and imaging with the antibody results and look for conditions such as IgG4-related orbital disease, idiopathic orbital inflammation, tumors, and sarcoidosis. An orbital biopsy may be considered when findings are unusual, imaging is unclear, or the condition does not respond as expected.
Could I develop an overactive thyroid later?
Yes, some people with euthyroid Graves orbitopathy later develop hyperthyroidism; studies in certain patient groups have found this in roughly one-quarter of patients. Regular follow-up with an endocrinologist can help determine when to repeat thyroid tests.

Get notified when new evidence is published on Euthyroid Graves orbitopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature.

    Muñoz-Ortiz J, Sierra-Cote MC, Zapata-Bravo E, et al.

    Systematic reviews 2020; (9(1)):201 doi:10.1186/s13643-020-01459-7.

    PMID: 32873324
  2. 2

    Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

    Marinò M, Ionni I, Lanzolla G, et al.

    Journal of endocrinological investigation 2020; (43(4)):401-411 doi:10.1007/s40618-019-01141-3.

    PMID: 31691261
  3. 3

    Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy.

    Ponto KA, Binder H, Diana T, et al.

    Thyroid : official journal of the American Thyroid Association 2015; (25(8)):942-8 doi:10.1089/thy.2015.0031.

    PMID: 26244413
  4. 4

    Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor.

    Latif R, Mezei M, Davies TF

    Endocrinology 2025; (166(2)) doi:10.1210/endocr/bqaf009.

    PMID: 39821041
  5. 5

    Stimulating Thyrotropin Receptor Antibodies Enhance the Expression of Both Thyrotropin Receptors and Insulin-Like Growth Factor 1 Receptors in Fibroblasts.

    Xiang P, Mezei M, Latif R, Davies TF

    Thyroid : official journal of the American Thyroid Association 2026; (36(8)):903-911 doi:10.1177/10507256261463222.

    PMID: 42374926
  6. 6

    TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types.

    Krieger CC, Perry JD, Morgan SJ, et al.

    Endocrinology 2017; (158(10)):3676-3683 doi:10.1210/en.2017-00528.

    PMID: 28938449
  7. 7

    Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.

    Neumann S, Krieger CC, Gershengorn MC

    European thyroid journal 2020; (9(Suppl 1)):59-65 doi:10.1159/000511538.

    PMID: 33511086
  8. 8

    Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model.

    Görtz GE, Moshkelgosha S, Jesenek C, et al.

    Endocrinology 2016; (157(10)):3771-3778 doi:10.1210/en.2016-1304.

    PMID: 27552248
  9. 9

    Coexpression of IGF1R and TSHR in extraocular muscles of patients with thyroid-associated orbitopathy.

    Chen KY, Lin CC, Chen WJ, Lai CC

    The British journal of ophthalmology 2026; doi:10.1136/bjo-2025-329199.

    PMID: 42760102
  10. 10

    Rapid and sensitive bioassay for thyroid-stimulating immunoglobulin detection in thyrotropin-binding inhibitory immunoglobulin-negative euthyroid Graves' orbitopathy.

    Hötte GJ, Van der Burg M, Dik WA, et al.

    European journal of endocrinology 2025; (193(5)):675-684 doi:10.1093/ejendo/lvaf210.

    PMID: 41074265
  11. 11

    Comparison of two different TSH-receptor antibody assays: A clinical practice study.

    van Balkum M, Schreurs MWJ, Visser WE, et al.

    Heliyon 2023; (9(12)):e22468 doi:10.1016/j.heliyon.2023.e22468.

    PMID: 38107298
  12. 12

    TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.

    Kahaly GJ, Diana T, Olivo PD

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(1)):97-106 doi:10.4158/EP-2019-0363.

    PMID: 32022598
  13. 13

    Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy.

    Hiromatsu Y, Eguchi H, Matsuo Y, et al.

    Endocrine journal 2020; (67(3)):347-352 doi:10.1507/endocrj.EJ19-0398.

    PMID: 31827052
  14. 14

    Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy.

    Sarić-Matutinović M, Diana T, Nedeljković-Beleslin B, et al.

    Journal of medical biochemistry 2022; (41(2)):211-220 doi:10.5937/jomb0-34718.

    PMID: 35510209
  15. 15

    Thyroid antibody-negative euthyroid Graves' ophthalmopathy.

    Tabasum A, Khan I, Taylor P, et al.

    Endocrinology, diabetes & metabolism case reports 2016; (2016()):160008 doi:10.1530/EDM-16-0008.

    PMID: 27284451
  16. 16

    Asymmetric proptosis in thyroid eye disease.

    Rana K, Garg D, Yong LSS, et al.

    International ophthalmology 2024; (44(1)):206 doi:10.1007/s10792-024-03141-6.

    PMID: 38678129
  17. 17

    Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy.

    Erdei A, Steiber Z, Molnar C, et al.

    BMC ophthalmology 2018; (18(1)):5 doi:10.1186/s12886-018-0672-y.

    PMID: 29329570
  18. 18

    Orbital Myositis: A Comprehensive Review and Reclassification.

    McNab AA

    Ophthalmic plastic and reconstructive surgery 2020; (36(2)):109-117 doi:10.1097/IOP.0000000000001429.

    PMID: 31261163
  19. 19

    Clinical-Radiological Patterns and Histopathological Outcomes in Non-Thyroid Extraocular Muscle Enlargement: Retrospective Case Series and Current Concepts.

    Savino G, Midena G, Tartaglione T, et al.

    Ophthalmic plastic and reconstructive surgery 2020; (36(3)):284-291 doi:10.1097/IOP.0000000000001533.

    PMID: 31789785
  20. 20

    Unmasking Orbital Myopathy: When Enlarged Extraocular Muscles Indicate More Than Thyroid Eye Disease: Report of Two Cases.

    Shinohara D, Abumanhal M, Takahashi Y

    Case reports in ophthalmological medicine 2026; (2026()):7712244 doi:10.1155/crop/7712244.

    PMID: 42729795
  21. 21

    Isolated superior rectus-levator complex enlargement: Inflammatory etiology, clinicoradiological features, and treatment outcomes.

    Yang MK, Ha SJ, Sa HS

    PloS one 2026; (21(9)):e0338854 doi:10.1371/journal.pone.0338854.

    PMID: 42776979
  22. 22

    Clinical course of thyroid function and thyroid associated-ophthalmopathy in patients with euthyroid Graves' disease.

    Suzuki N, Noh JY, Kameda T, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2018; (12()):739-746 doi:10.2147/OPTH.S158967.

    PMID: 29719374
  23. 23

    Euthyroid graves' ophthalmopathy in a Chinese population: A cross-sectional follow-up study.

    Lai KK, Ali Abdulla Aljufairi FM, Sebastian JU, et al.

    European journal of ophthalmology 2024; (34(5)):1432-1437 doi:10.1177/11206721241229470.

    PMID: 38444235
  24. 24

    Correlation between extraocular muscle enlargement and thyroid autoantibodies in thyroid eye disease.

    Koizumi T, Tanaka T, Umeda K, et al.

    Japanese journal of ophthalmology 2024; (68(3)):250-258 doi:10.1007/s10384-024-01061-7.

    PMID: 38609717

This page explains how euthyroid Graves orbitopathy is evaluated for informational purposes only and does not constitute medical advice. Your endocrinologist and eye specialist should interpret your antibody tests, scans, and thyroid monitoring plan.

Guide contents Euthyroid Graves orbitopathy
Research & Literature
02 Tracking the Journey